- Home
- ENTX
ENTX
Entera Bio Ltd.
as 07-26-2024 4:00pm EST
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
| Founded: | 2010 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 71.6M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 53.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $3.35 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Entera Bio Ltd. (ENTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Taitel Haya | ENTX | Director | Jan 12 '24 | Buy | $0.99 | 9,500 | $9,405.00 | 35,115 | SEC Form 4 |
| Taitel Haya | ENTX | Director | Jan 10 '24 | Buy | $0.77 | 7,615 | $5,863.55 | 25,615 | SEC Form 4 |
| Toledano Miranda Jayne | ENTX | Chief Executive Officer | Dec 22 '23 | Buy | $0.71 | 23,952 | $17,005.92 | 110,752 | SEC Form 4 |
| LIEBERMAN GERALD M | ENTX | Director | Dec 22 '23 | Buy | $0.71 | 23,952 | $17,005.92 | 226,961 | SEC Form 4 |
Latest Entera Bio Ltd. News
ENTX Breaking Stock News: Dive into ENTX Ticker-Specific Updates for Smart Investing
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
2 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Simply Wall St.
2 months ago
Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Motley Fool
2 months ago
3 Mistakes That Can Get Your Costco Membership Canceled
Compare ENTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENTX Entera Bio Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.